Douglas Manion
Director/Board Member bij Lakewood-Amedex, Inc.
Vermogen: 51 848 $ op 31-03-2024
Profiel
Douglas J.
Manion is currently a Director at Lakewood-Amedex, Inc. He was previously the President, Chief Executive Officer & Director at Aclaris Therapeutics, Inc. from 2023 to 2024, Chairman & Chief Executive Officer at Kleo Pharmaceuticals, Inc. from 2020 to 2021, and Senior VP & Head-Specialty Development at Bristol Myers Squibb Co. from 2014 to 2016.
He also served as a Non-Executive Director at Celleron Therapeutics Ltd.
and Executive Vice President-Research & Development at Arena Pharmaceuticals, Inc. from 2021 to 2022.
Manion received his undergraduate and doctorate degrees from the University of Ottawa.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
01-01-2024 | 41 813 ( 0.06% ) | 51 848 $ | 31-03-2024 |
Actieve functies van Douglas Manion
Bedrijven | Functie | Begin |
---|---|---|
Lakewood-Amedex, Inc.
Lakewood-Amedex, Inc. Pharmaceuticals: MajorHealth Technology Lakewood-Amedex, Inc. engages in the development of treatment for serious infectious diseases. Its product pipeline include Nu-3 cDFU, Nu-3 Oral Mucositis, Nu-8 cUTI, and Nu-8 (Cystic Fibrosis). The company is headquartered in Sarasota, FL. | Director/Board Member | 25-01-2021 |
Eerdere bekende functies van Douglas Manion
Bedrijven | Functie | Einde |
---|---|---|
ACLARIS THERAPEUTICS, INC. | Chief Executive Officer | 16-01-2024 |
ARENA PHARMACEUTICALS | Chief Tech/Sci/R&D Officer | 01-03-2022 |
Kleo Pharmaceuticals, Inc.
Kleo Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Kleo Pharmaceuticals, Inc. is a biotechnology company, which engages in the development of biospecific compounds designed to emulate and enhance the activity of biologics. Its compounds are designed to direct the immune system to destroy cancerous or virally infected cells, and treatment of multiple myeloma and COVID-19. It offers Antibody Recruiting Molecules (ARMs),Synthetic Antibody Mimics (SyAMs), and Monoclonal Antibody Therapy Enhancers (MATEs) pipeline. The company was founded by David A. Spiegel and Roy Prieb in 2015 and is headquartered in New Haven, CT. | Chief Executive Officer | 31-01-2021 |
BRISTOL-MYERS SQUIBB COMPANY | Chief Tech/Sci/R&D Officer | 19-02-2013 |
Celleron Therapeutics Ltd.
Celleron Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Celleron Therapeutics Ltd. is an oncology company based in Oxford, UK. The company has deep relationships with Oxford University and is located on the Oxford Science Park. Celleron is focused on developing new and innovative therapies to treat cancer, with a particular emphasis on clinical development. The British company is developing a novel group of clinical products, supported by predictive companion diagnostics, that act through defined molecular mechanisms to prevent cancer cell growth. Celleron's lead products are in clinical trials, supported by a biomarker platform that allows responsive patients to be identified. The company was founded in 2004 and is led by CEO Nick la Thangue. | Director/Board Member | - |
Opleiding van Douglas Manion
University of Ottawa | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
ACLARIS THERAPEUTICS, INC. | Health Technology |
Bedrijven in privébezit | 4 |
---|---|
Arena Pharmaceuticals, Inc.
Arena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arena Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel drugs that target G protein-coupled receptors. It offers drugs for treatment in the field of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company was founded by Dominic P. Behan and Jack Lief on April 14, 1997 and is headquartered in Park City, UT. | Health Technology |
Celleron Therapeutics Ltd.
Celleron Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Celleron Therapeutics Ltd. is an oncology company based in Oxford, UK. The company has deep relationships with Oxford University and is located on the Oxford Science Park. Celleron is focused on developing new and innovative therapies to treat cancer, with a particular emphasis on clinical development. The British company is developing a novel group of clinical products, supported by predictive companion diagnostics, that act through defined molecular mechanisms to prevent cancer cell growth. Celleron's lead products are in clinical trials, supported by a biomarker platform that allows responsive patients to be identified. The company was founded in 2004 and is led by CEO Nick la Thangue. | Health Technology |
Lakewood-Amedex, Inc.
Lakewood-Amedex, Inc. Pharmaceuticals: MajorHealth Technology Lakewood-Amedex, Inc. engages in the development of treatment for serious infectious diseases. Its product pipeline include Nu-3 cDFU, Nu-3 Oral Mucositis, Nu-8 cUTI, and Nu-8 (Cystic Fibrosis). The company is headquartered in Sarasota, FL. | Health Technology |
Kleo Pharmaceuticals, Inc.
Kleo Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Kleo Pharmaceuticals, Inc. is a biotechnology company, which engages in the development of biospecific compounds designed to emulate and enhance the activity of biologics. Its compounds are designed to direct the immune system to destroy cancerous or virally infected cells, and treatment of multiple myeloma and COVID-19. It offers Antibody Recruiting Molecules (ARMs),Synthetic Antibody Mimics (SyAMs), and Monoclonal Antibody Therapy Enhancers (MATEs) pipeline. The company was founded by David A. Spiegel and Roy Prieb in 2015 and is headquartered in New Haven, CT. | Commercial Services |